印度比哈尔邦内脏利什曼病病例漏报情况估计。
Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India.
机构信息
Division of Epidemiology and Biostatistics, Rajendra Memorial Research Institute of Medical Science, Indian Council of Medical Research, Patna, Bihar, India.
出版信息
Am J Trop Med Hyg. 2010 Jan;82(1):9-11. doi: 10.4269/ajtmh.2010.09-0235.
Abstract
We estimated the level of under-reporting of visceral leishmaniasis (VL) cases by comparing the actual reported cases with those expected as estimated using age- and sex-stratified incidence proportions obtained in a cohort of 31,324 persons. The average incidence proportion of VL cases in study population was 5.7/1,000 (95% confidence interval [CI] = 4.88-6.54) and 1.09/1,000 persons (95% CI = 0.99-1.20) based on the reported cases in two primary health centers. The overall magnitude of VL cases not reported to the government agencies was higher by a factor 4.17 (95% CI = 3.75-4.63) than for reported cases. The levels of under-reporting were 4.74 (95% CI = 4.11-5.47) in males and 3.51 (95% CI = 2.99-4.11) in females with no significant difference (P > 0.05). It was significantly higher in persons >or= 30 years of age than in persons 30 years of age (P < 0.05).
摘要
我们通过将实际报告的病例与使用 31324 人队列中获得的按年龄和性别分层的发病率比例估计的预期病例进行比较，估计了内脏利什曼病（VL）病例的漏报水平。研究人群中 VL 病例的平均发病率比例为 5.7/1000（95%置信区间[CI] = 4.88-6.54）和 1.09/1000 人（95%CI = 0.99-1.20）基于两个初级保健中心报告的病例。与报告病例相比，未向政府机构报告的 VL 病例总体规模高出 4.17 倍（95%CI = 3.75-4.63）。漏报率为男性 4.74（95%CI = 4.11-5.47），女性 3.51（95%CI = 2.99-4.11），无显著差异（P > 0.05）。年龄≥30 岁的人群明显高于 30 岁的人群（P < 0.05）。
相似文献
1
Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India.印度比哈尔邦内脏利什曼病病例漏报情况估计。
Am J Trop Med Hyg. 2010 Jan;82(1):9-11. doi: 10.4269/ajtmh.2010.09-0235.
2
Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.印度比哈尔邦通过被动病例报告对内脏利什曼病的严重漏报情况。
Trop Med Int Health. 2006 Jun;11(6):899-905. doi: 10.1111/j.1365-3156.2006.01647.x.
3
Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India.印度比哈尔邦一疾病流行区内脏利什曼病的无症状感染。
Am J Trop Med Hyg. 2010 Sep;83(3):502-6. doi: 10.4269/ajtmh.2010.09-0345.
4
Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India.印度比哈尔邦一个流行地区内脏利什曼病的年发病率。
Trop Med Int Health. 2010 Jul;15 Suppl 2:4-11. doi: 10.1111/j.1365-3156.2010.02517.x. Epub 2010 May 6.
5
Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India.内脏利什曼病的诊断和报告延误成为尼泊尔和印度及时采取应对行动的障碍。
BMC Infect Dis. 2015 Feb 6;15:43. doi: 10.1186/s12879-015-0767-5.
6
Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008.印度比哈尔邦穆扎法尔布尔地区 1990 年至 2008 年内脏利什曼病疫情。
PLoS One. 2011 Mar 4;6(3):e14751. doi: 10.1371/journal.pone.0014751.
7
Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India.印度比哈尔邦内脏利什曼病负担、死亡率和就医途径的变化。
Parasit Vectors. 2017 Dec 7;10(1):601. doi: 10.1186/s13071-017-2530-9.
8
Low castes have poor access to visceral leishmaniasis treatment in Bihar, India.在印度比哈尔邦，低种姓人群获得内脏利什曼病治疗的机会有限。
Trop Med Int Health. 2012 May;17(5):666-73. doi: 10.1111/j.1365-3156.2012.02960.x. Epub 2012 Mar 5.
9
Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased Transmission at the Village Level in Bihar, India.内脏利什曼病-人类免疫缺陷病毒合并感染是印度比哈尔邦村庄层面传播增加的预测因素。
Front Cell Infect Microbiol. 2021 Mar 11;11:604117. doi: 10.3389/fcimb.2021.604117. eCollection 2021.
10
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India.印度比哈尔邦高度流行地区内脏利什曼病的纵向血清流行病学研究。
Am J Trop Med Hyg. 2009 Mar;80(3):345-6.
引用本文的文献
1
The story of elimination of visceral leishmaniasis (kala-azar) in India-Challenges towards sustainment.印度消除内脏利什曼病（黑热病）的历程——维持消除成果面临的挑战
PLoS Negl Trop Dis. 2025 Aug 19;19(8):e0013321. doi: 10.1371/journal.pntd.0013321. eCollection 2025 Aug.
2
Leishmaniasis in Humans and Animals: A One Health Approach for Surveillance, Prevention and Control in a Changing World.人类和动物的利什曼病：变化世界中监测、预防和控制的“同一健康”方法
Trop Med Infect Dis. 2024 Oct 28;9(11):258. doi: 10.3390/tropicalmed9110258.
3
Arsenic exposure to mouse visceral leishmaniasis model through their drinking water linked to the disease exacerbation via modulation in host protective immunity: a preclinical study.通过饮用水向感染内脏利什曼病的小鼠模型暴露砷与通过调节宿主保护性免疫导致疾病恶化有关：一项临床前研究。
Sci Rep. 2023 Dec 5;13(1):21461. doi: 10.1038/s41598-023-48642-z.
4
Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review.心脏功能不佳患者新冠病毒感染后发生脓疱性皮肤利什曼病：病例报告及文献综述
Trop Med Infect Dis. 2023 Sep 10;8(9):443. doi: 10.3390/tropicalmed8090443.
5
Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.估算利什曼病疫苗的全球需求曲线：基于全球疾病负担估计的可推广方法。
PLoS Negl Trop Dis. 2022 Jun 13;16(6):e0010471. doi: 10.1371/journal.pntd.0010471. eCollection 2022 Jun.
6
Overcoming roadblocks in the development of vaccines for leishmaniasis.克服利什曼病疫苗研发中的障碍。
Expert Rev Vaccines. 2021 Nov;20(11):1419-1430. doi: 10.1080/14760584.2021.1990043. Epub 2021 Nov 2.
7
Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.通过在印度比哈尔邦实施基于卫生机构的哨点监测系统，改善黑热病病例管理。
PLoS Negl Trop Dis. 2021 Aug 24;15(8):e0009598. doi: 10.1371/journal.pntd.0009598. eCollection 2021 Aug.
8
Development and Evaluation of Active Case Detection Methods to Support Visceral Leishmaniasis Elimination in India.发展和评估主动病例检测方法以支持印度内脏利什曼病消除。
Front Cell Infect Microbiol. 2021 Mar 24;11:648903. doi: 10.3389/fcimb.2021.648903. eCollection 2021.
9
Optimizing Village-Level Targeting of Active Case Detection to Support Visceral Leishmaniasis Elimination in India.优化村级主动病例检测目标定位，以支持印度内脏利什曼病消除。
Front Cell Infect Microbiol. 2021 Mar 24;11:648847. doi: 10.3389/fcimb.2021.648847. eCollection 2021.
10
Towards a Sustainable Vector-Control Strategy in the Post Kala-Azar Elimination Era.迈向卡巴尔消除时代的可持续病媒控制策略。
Front Cell Infect Microbiol. 2021 Mar 9;11:641632. doi: 10.3389/fcimb.2021.641632. eCollection 2021.
本文引用的文献
1
Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.印度比哈尔邦通过被动病例报告对内脏利什曼病的严重漏报情况。
Trop Med Int Health. 2006 Jun;11(6):899-905. doi: 10.1111/j.1365-3156.2006.01647.x.
2
Kala-azar--progress against a neglected disease.黑热病——抗击一种被忽视疾病的进展
N Engl J Med. 2002 Nov 28;347(22):1793-4. doi: 10.1056/NEJMe020133.
3
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.内脏利什曼病：控制、诊断和治疗的现状以及拟议的研发议程。
Lancet Infect Dis. 2002 Aug;2(8):494-501. doi: 10.1016/s1473-3099(02)00347-x.
4
Socio-economics of visceral leishmaniasis in Bihar (India).印度比哈尔邦内脏利什曼病的社会经济学
Trans R Soc Trop Med Hyg. 2000 Mar-Apr;94(2):156-7. doi: 10.1016/s0035-9203(00)90255-4.
5
Epidemiology of visceral leishmaniasis in India.印度内脏利什曼病的流行病学
Natl Med J India. 1999 Mar-Apr;12(2):62-8.
6
Leishmaniasis. Public health aspects and control.利什曼病。公共卫生方面及防治
Clin Dermatol. 1996 Sep-Oct;14(5):417-23. doi: 10.1016/0738-081x(96)00057-0.
7
Changes in age incidence of kala-azar in India.印度黑热病年龄发病率的变化。
Indian J Public Health. 1995 Jan-Mar;39(1):26.
8
An estimate of kala azar in 1991 in district Vaishali and Bihar.1991年比哈尔邦瓦伊沙利地区黑热病的一项估计。
J Commun Dis. 1994 Jun;26(2):120-2.
9
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).比哈尔邦黑热病（包括黑热病后皮肤利什曼病）的流行病学、临床及治疗特征
Trans R Soc Trop Med Hyg. 1984;78(3):391-8. doi: 10.1016/0035-9203(84)90131-7.
10
Control of the leishmaniases. Report of a WHO Expert Committee.利什曼病的防治。世界卫生组织专家委员会报告。
World Health Organ Tech Rep Ser. 1990;793:1-158.
Zotero 插件